Only a moderate to high dose of the peptide showed beneficial effects (mediated by GHS-R1a) on colitis by suppressing inhibitory κB-α (IκB-α) degradation and reducing nuclear expression of NF-κB p65. The gene discussed is NFKB1; the disease is colitis.